Polymorphonuclear neutrophils promote rFGF-2-induced angiogenesis in vivo

J Surg Res. 2003 Jan;109(1):37-42. doi: 10.1016/s0022-4804(02)00020-3.

Abstract

Background: The role of neutrophils in angiogenesis remains largely unknown. Recent evidence has shown that polymorphonuclear neutrophils (PMNs) produce several proangiogenic cytokines, including VEGF, TNF-alpha, IL-1, IL-6, and IL-8. In addition, PMN-derived proteinases promote endothelial cell migration. We hypothesized that PMNs may facilitate angiogenesis and that reducing circulating PMNs might alter the host angiogenic response.

Materials and methods: We utilized a corneal pocket assay to compare rFGF-2-induced vessel formation in the corneas of mice with normal levels of circulating neutrophils to those in a neutropenic state. Circulating PMNs were reduced using serial intraperitoneal injections of monoclonal antibody to Gr-1. Slow release rFGF2 pellets were implanted into the corneas of neutropenic mice and controls. Corneal neovascularization, measured as vessel length and area of vessel in-growth, was quantified using slit-lamp microscopy on day 7.

Results: The average number of circulating PMNs was significantly reduced in the experimental group compared to the control group on days 1-7 (P < 0.05). No statistical differences in circulating monocytes or lymphocytes were observed from days 0 to 6. Mice in the experimental group had a vascular area of 2.58 +/- 0.2 mm(2) compared to 3.55 +/- 0.3 mm(2) in the control group (P < 0.05).

Conclusions: Corneal neovascularization in response to rFGF-2 is diminished by PMN depletion. PMNs play an important role in facilitating rFGF-2-induced angiogenesis.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Cornea / blood supply
  • Cornea / cytology
  • Drug Implants
  • Female
  • Fibroblast Growth Factor 2 / administration & dosage
  • Fibroblast Growth Factor 2 / pharmacology*
  • Injections, Intraperitoneal
  • Leukocyte Count
  • Macrophages
  • Mice
  • Neovascularization, Physiologic / drug effects*
  • Neutropenia
  • Neutrophils / physiology*
  • Recombinant Proteins / pharmacology
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Drug Implants
  • Recombinant Proteins
  • Fibroblast Growth Factor 2